| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PROS.10025 |
| P698 | PubMed publication ID | 11746276 |
| P2093 | author name string | S E Crawford | |
| S C Campbell | |||
| N P Bouck | |||
| M R Pins | |||
| F K Reiher | |||
| J A Doll | |||
| P2860 | cites work | Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and its relation to androgen receptor | Q73139218 |
| Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer | Q73223388 | ||
| Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity | Q73309958 | ||
| Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia | Q73330004 | ||
| Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts | Q73436686 | ||
| Vascular density is a predictor of cancer-specific survival in prostatic carcinoma | Q73690891 | ||
| Changes in growth factor expression in the ageing prostate may disrupt epithelial-stromal homeostasis | Q74175806 | ||
| Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor | Q74601078 | ||
| Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer | Q77164555 | ||
| Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma | Q77340398 | ||
| Tumor induction of VEGF promoter activity in stromal cells | Q77349243 | ||
| FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation | Q78015006 | ||
| Transplacental carcinogenesis by stilbestrol | Q95784569 | ||
| Transforming growth factor-beta complexes with thrombospondin | Q24642789 | ||
| Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity | Q24674570 | ||
| Pigment epithelium-derived factor: a potent inhibitor of angiogenesis | Q28139159 | ||
| VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms | Q28141270 | ||
| Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats | Q28373686 | ||
| Thrombospondin-1 is a major activator of TGF-beta1 in vivo | Q28513856 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor | Q33556391 | ||
| What might a stromal response mean to prostate cancer progression? | Q33715210 | ||
| A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin | Q33763790 | ||
| Growth factors and epithelial-stromal interactions in prostate cancer development | Q33955332 | ||
| Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells | Q35786924 | ||
| Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis | Q36256017 | ||
| A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. | Q37402504 | ||
| Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting | Q38470808 | ||
| Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells | Q38472948 | ||
| Evidence of independent origin of multiple tumors from patients with prostate cancer | Q38529357 | ||
| Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies | Q39424954 | ||
| Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells | Q39999738 | ||
| The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts | Q40823128 | ||
| Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo | Q41051413 | ||
| The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. | Q41506143 | ||
| Assay and purification of naturally occurring inhibitor of angiogenesis | Q41703789 | ||
| Influence of tumour size on human prostate tumour metastasis in athymic nude mice | Q42374194 | ||
| Topography of neovascularity in human prostate carcinoma | Q42477426 | ||
| Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis | Q42477520 | ||
| Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients | Q42492515 | ||
| Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment | Q47901241 | ||
| Methylation and silencing of the Thrombospondin-1 promoter in human cancer | Q48192580 | ||
| Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. | Q53516782 | ||
| An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer . preliminary results and therapeutic implications. | Q54118091 | ||
| Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. | Q54127845 | ||
| Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro | Q67466166 | ||
| Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 | Q71644976 | ||
| Association of transforming growth factor-β1 with prostate cancer: An immunohistochemical study | Q72067102 | ||
| Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate | Q73048634 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 293-305 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | The Prostate | Q7758608 |
| P1476 | title | Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate | |
| P478 | volume | 49 |
| Q37258981 | A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer |
| Q33607836 | Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. |
| Q35038768 | Angiogenesis as a target for cancer therapy |
| Q34997082 | Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches |
| Q40449157 | Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. |
| Q54375534 | Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice. |
| Q37426688 | Beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1. |
| Q39818502 | CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis |
| Q24304353 | Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose |
| Q81133270 | Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model |
| Q40171674 | Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. |
| Q35820978 | Constitutive and Inducible Expression of Invasion-related Factors in PC-3 Prostate Cancer Cells |
| Q36452714 | Current status and perspective of antiangiogenic therapy for cancer: urinary cancer |
| Q36469815 | Current status of anti-angiogenesis therapy for prostate cancer. |
| Q41212675 | Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. |
| Q35048524 | Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice |
| Q37721529 | Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls |
| Q37369734 | Expression and localization of members of the thrombospondin family during final follicle maturation and corpus luteum formation and function in the bovine ovary. |
| Q42673080 | Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer |
| Q24793622 | Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA |
| Q42464525 | Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer |
| Q33597813 | FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1 |
| Q33733638 | Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts |
| Q36456511 | Future innovations in treating advanced prostate cancer |
| Q46334676 | Genome‐wide scan of brothers: Replication and fine mapping of prostate cancer susceptibility and aggressiveness loci |
| Q37258877 | Growth factors in benign prostatic hyperplasia: basic science implications |
| Q39970929 | HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells |
| Q34360616 | Human prostate cancer risk factors |
| Q47982349 | Increased and localized accumulation of chondroitin sulphate proteoglycans in the hyperplastic human prostate |
| Q36321428 | Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins |
| Q37077753 | Inorganic Arsenic-Related Changes in the Stromal Tumor Microenvironment in a Prostate Cancer Cell-Conditioned Media Model |
| Q36735258 | Integrin-Linked Kinase: It's Role in the Vascular System |
| Q37690429 | Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression |
| Q42620772 | Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy |
| Q27024795 | Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer |
| Q79443116 | Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue |
| Q28513340 | Pigment epithelium–derived factor regulates the vasculature and mass of the prostate and pancreas |
| Q37513161 | Prostate angiogenesis in development and inflammation |
| Q33302103 | SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas |
| Q53285931 | Similar expression to FGF (Sef) reduces endometrial adenocarcinoma cells proliferation via inhibiting fibroblast growth factor 2-mediated MAPK/ERK signaling pathway. |
| Q40813190 | Stereological evaluation of fibronectin in the periurethral region of the transitional zone from normal human prostates compared with benign prostatic hyperplasia. |
| Q38139831 | Targeting fibroblast growth factor pathways in prostate cancer |
| Q21245714 | Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors |
| Q26770428 | Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects |
| Q40426766 | The remote effects of intravitreal anti-VEGF therapy |
| Q78384186 | The role of fibroblast growth factors in vascular development |
| Q38113142 | Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects |
| Q36140753 | Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). |
| Q39705442 | Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation |
| Q38283244 | Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis |
| Q39670808 | Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1. |
| Q39598551 | Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer |
Search more.